



Bristol-Myers Squibb (BMY)

Updated February 6th, 2022 by Nathan Parsh

Key Metrics

Current Price:	\$65	5 Year CAGR Estimate:	15.7%	Market Cap:	\$144 billion
Fair Value Price:	\$105	5 Year Growth Estimate:	3.0%	Ex-Dividend Date:	3/30/2022 ¹
% Fair Value:	62%	5 Year Valuation Multiple Estimate:	10.1%	Dividend Payment Date:	5/5/2022 ²
Dividend Yield:	3.3%	5 Year Price Target	\$122	Years Of Dividend Growth:	15
Dividend Risk Score:	A	Retirement Suitability Score:	A	Last Dividend Increase:	10.2%

Overview & Current Events

Bristol-Myers Squibb was created when Bristol-Myers and Squibb merged on October 4th, 1989. Bristol-Myers can trace its corporate beginnings back to 1887. Today this leading drug maker of cardiovascular and anti-cancer therapeutics has annual revenues of about \$47 billion.

Bristol-Myers closed on its \$74 billion purchase of Celgene Corporation (CELG) on 11/20/2019. We expect this acquisition to factor heavily into Bristol-Myers' results for the years to come.

Bristol-Myers reported fourth quarter and full year earnings results on 2/4/2022. For the quarter, revenue improved 8.1% to \$12 billion, which was in-line with analysts' expectations. Adjusted earnings-per-share of \$1.83 compared favorably to adjusted earnings-per-share of \$1.46 in the prior year and was \$0.03 above estimates. For the year, revenue grew 9% to \$46.4 billion with adjusted earnings-per-share of \$7.51 comparing very favorably to adjusted earnings-per-share of \$6.44 in 2020.

U.S. revenues improved 12% to \$7.5 billion while international was up 4%. Adjusting for currency exchange, international revenue grew 7%. For the quarter, Revlimid sales increased 1% to \$3.3 billion. U.S. sales were up slightly due to longer treatment duration, but were partially offset by generic competition in Canada. Revlimid is expected to see a decline in revenue for 2022. Eliquis, which prevents blood clots, grew 18% to \$2.7 billion due largely to strength in the U.S. and key international markets. Eliquis has become the top oral anticoagulant in several international countries since 2019 and had nearly \$11 billion in revenue for the year, which was a 17% increase from 2020. Opdivo, which treats cancers such as advanced renal carcinoma, experienced accelerated growth in the U.S., with total sales up 11% to \$2.0 billion. Revenue for Orencia, which treats rheumatoid arthritis, was flat at \$864 million. Gross margins expanded 660 basis points to 80.3% due to an impairment charge in the prior year and lower unwinding of inventory purchase price accounting adjustments. In December of 2021, the company authorized a \$15 billion share repurchase to take place over several years. The company will conduct an accelerated share repurchase program of up to \$5 billion in the first quarter of the current year.

Bristol-Myers provided an outlook for 2022 as well. The company expects adjusted earnings-per-share in a range of \$7.65 to \$7.95 with revenue of nearly \$47 billion for the year. We have initiated our forecast accordingly.

Growth on a Per-Share Basis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
EPS	\$1.16	\$1.54	\$1.20	\$0.93	\$2.65	\$3.01	\$3.98	\$4.69	\$6.44	\$7.51	\$7.80	\$9.04
DPS	\$1.37	\$1.41	\$1.45	\$1.49	\$1.53	\$1.57	\$1.60	\$1.64	\$1.80	\$1.96	\$2.16	\$2.76
Shares³	1630	1641	1662	1661	1664	1625	1623	1918	2252	2219	2200	2100

Bristol-Myers' earnings-per-share saw a small increase in the years during and directly following the last recession. Since 2012, earnings results have been varied. Overall, Bristol-Myers has seen earnings-per-share grow at a rate of 23.1% per

¹ Estimated ex-dividend date

² Estimated dividend payment date

³ In millions of shares

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Bristol-Myers Squibb (BMY)

Updated February 6th, 2022 by Nathan Parsh

year over the last decade, but much of this growth has occurred over the past three years. Due to the unpredictable nature of the company's results, we project 3% growth through 2027.

Bristol-Myers has increased its dividend at a CAGR of 3.1% over the past 10 years. The trend had been that shareholders receive a \$0.01 dividend-per-quarter raise each year. However, that was broken over the past few years and the company increased its dividend by 10.2% for the 2/1/2022 payment. We project 5% dividend growth annually over the next five years.

Valuation Analysis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Now	2027
Avg. P/E	28.7	28.6	43.6	---	23.9	20.4	13.0	13.7	9.6	8.3	8.3	13.5
Avg. Yld.	4.1%	3.2%	2.8%	2.3%	2.4%	2.8%	3.2%	2.6%	2.9%	3.1%	3.3%	2.3%

While Bristol-Myers was growing earnings from 2008-2012, the stock's price-to-earnings ratio barely budged. When earnings started to decline, the stock price accelerated, which led to some very high earnings multiples. We are reaffirming our target multiple of 13.5x earnings. This brings Bristol-Myers' valuation more in line with large pharma companies in the same situation. Bristol-Myers shares have increased \$8, or 14%, since our 10/27/2021 update. Based off of guidance for 2022, shares have a P/E multiple of 8.3. Valuation could add 10.1% to annual returns if shares of Bristol-Myers reach our target by 2027.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
Payout	118%	92%	121%	160%	58%	52%	40%	35%	28%	26%	28%	30%

The company's competitive advantage is its ability to either create (through research & development) or acquire patents for pharmaceuticals with high potential revenue. Bristol-Myers top three selling pharmaceuticals, Revlimid, Opdivo and Eliquis, have shown solid growth rates and are expected to see high peak annual sales. The addition of Celgene should add to the top and bottom lines. Bristol-Myers saw earnings increase during the last recession, which is quite normal for drug companies. Even in a recession, people will seek treatment for health problems, especially those of the cancer variety.

Final Thoughts & Recommendation

After fourth quarter results, Bristol-Myers Squibb is now expected to offer a total annual return of 15.7% through 2027, down from our prior estimate of 17.6%. Projected returns stem from a 3% earnings growth rate, 3.3% starting dividend yield, and a low double-digit tailwind from possible multiple expansion. Bristol-Myers saw growth in most of its top products once again. We have raised our five-year price target \$5 to \$122 due to the company's guidance for the year and reiterate our buy rating on Bristol-Myers due to projected returns.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Bristol-Myers Squibb (BMY)

Updated February 6th, 2022 by Nathan Parsh

Income Statement Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Revenue	21244	17621	16385	15879	16560	19427	20776	22561	26145	42518
Gross Profit	15646	13011	11766	11947	12651	14458	14762	16094	18067	30745
Gross Margin	73.6%	73.8%	71.8%	75.2%	76.4%	74.4%	71.1%	71.3%	69.1%	72.3%
SG&A Exp.	5170	5175	5104	5699	5001	4979	4751	4551	4871	7661
D&A Exp.	628	681	763	467	376	382	789	637	1746	10380
Operating Profit	6637	3932	2931	1714	1730	4467	3446	5114	5913	2177
Op. Margin	31.2%	22.3%	17.9%	10.8%	10.4%	23.0%	16.6%	22.7%	22.6%	5.1%
Net Profit	3709	1960	2563	2004	1565	4457	1007	4920	3439	-9015
Net Margin	17.5%	11.1%	15.6%	12.6%	9.5%	22.9%	4.8%	21.8%	13.2%	-21.2%
Free Cash Flow	4473	6393	3008	2622	1285	1843	4220	6115	7374	13299
Income Tax	1721	-161	311	352	446	1408	4156	1021	1515	2124

Balance Sheet Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total Assets	32970	35897	38592	33749	31748	33707	33551	34986	129944	118481
Cash & Equivalents	5776	1656	3586	5571	2385	4237	5421	6911	12346	14546
Acc. Receivable	2250	1708	1690	2100	2948	3774	4347	4636	6476	7219
Inventories	1384	1657	1498	1560	1221	1241	1166	1195	4293	2074
Goodwill & Int.	8710	16413	9414	8780	8300	8260	8073	7629	86457	73790
Total Liabilities	17103	22259	23356	18766	17324	17360	21704	20859	78246	80599
Accounts Payable	2603	2202	2559	2487	1565	1664	2248	1892	2445	2713
Long-Term Debt	5491	7394	8340	7832	6689	6708	7962	7349	46733	50676
Total Equity	15956	13623	15154	14852	14266	16177	11741	14031	51598	37822
LTD/E Ratio	0.34	0.54	0.55	0.53	0.47	0.41	0.68	0.52	0.91	1.34

Profitability & Per Share Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Return on Assets	11.6%	5.7%	6.9%	5.5%	4.8%	13.6%	3.0%	14.4%	4.2%	-7.3%
Return on Equity	23.4%	13.3%	17.8%	13.4%	10.7%	29.3%	7.2%	38.2%	10.5%	-20.2%
ROIC	17.5%	9.2%	11.5%	8.6%	7.1%	20.2%	4.7%	23.8%	5.7%	-9.6%
Shares Out.	1717	1688	1662	1670	1679	1680	1652	1637	1712	2258
Revenue/Share	12.37	10.44	9.86	9.51	9.86	11.56	12.58	13.78	15.27	18.83
FCF/Share	2.61	3.79	1.81	1.57	0.77	1.10	2.55	3.74	4.31	5.89

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.